Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum

Biological Psychiatry

Volumn 57, Issue 5, 2005, Pages 533-542

  Alimohamad, Heidar ^a   Rajakumar, Nagalingam ^a,b   Seah, Yam Hong ^a   Rushlow, Walter ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Antipsychotics; GSK 3; Prefrontal cortex; Striatum; Wnt; Catenin

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMPHETAMINE; APOMORPHINE; BETA CATENIN; CLOZAPINE; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; NEUROLEPTIC AGENT; QUINPIROLE; RACLOPRIDE; RISPERIDONE; RITANSERIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME PHOSPHORYLATION; FEMALE; IMMUNOCYTOCHEMISTRY; LONG TERM EXPOSURE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; WESTERN BLOTTING;

EID: 14644389398     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.11.036     Document Type: Article

References (61)

1. H. Aberle, A. Bauer, J. Stappert, A. Kispert, R. Kemler beta-catenin is a target for the ubiquitin-proteasome pathway EMBO J 16 1997 3797 3804
2. C. Beasley, D. Cotter, N. Khan, C. Pollard, P. Sheppard, I. Varndell Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia Neurosci Lett 302 2001 117 120
3. J.M. Beaulieu, T.D. Sotnikova, W.D. Yao, L. Kockeritz, J.R. Woodgett, R.R. Gainetdinov Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade Proc Natl Acad Sci U S A 101 2004 5099 5104
4. J. Behrens, J.P. von Kries, M. Kuhl, L. Bruhn, D. Wedlich, R. Grosschedl Functional interaction of beta-catenin with the transcription factor LEF-1 Nature 382 1996 638 642
5. H.W. Berendse, Y. Galis-de Graaf, H.J. Groenewegen Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat J Comp Neurol 316 1992 314 347
6. P. Bhanot, M. Brink, C.H. Samos, J.C. Hsieh, Y. Wang, J.P. Macke A new member of the frizzled family from Drosophila functions as a Wingless receptor Nature 382 1996 225 230
7. K. Brami-Cherrier, E. Valjent, M. Garcia, C. Pages, R.A. Hipskind, J. Caboche Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons a new route to cAMP response element-binding protein phosphorylation J Neurosci 22 2002 8911 8921
8. M. Brannon, M. Gomperts, L. Sumoy, R.T. Moon, D. Kimelman A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus Genes Dev 11 1997 2359 2370
9. K. Broich, F. Grunwald, S. Kasper, E. Klemm, H.J. Biersack, H.J. Moller D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects Pharmacopsychiatry 31 1998 159 162
10. K.M. Cadigan, R. Nusse Wnt signaling a common theme in animal development Genes Dev 11 1997 3286 3305
11. G. Chen, L.D. Huang, Y.M. Jiang, H.K. Manji The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 J Neurochem 72 1999 1327 1330
12. D. Cotter, R. Kerwin, S. al Sarraji, J.P. Brion, A. Chadwich, S. Lovestone Abnormalities of Wnt signaling in schizophrenia-evidence for neurodevelopmental abnormality Neuroreport 9 1998 1379 1383
13. G.V. De Ferrari, N.C. Inestrosa Wnt signaling function in Alzheimer's disease Brain Res Brain Res Rev 33 2000 1 12
14. B.W. Doble, J.R. Woodgett GSK-3 tricks of the trade for a multi-tasking kinase J Cell Sci 116 2003 1175 1186
15. E.S. Emamian, D. Hall, M.J. Birnbaum, M. Karayiorgou, J.A. Gogos Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia Nat Genet 36 2004 131 137
16. D.J. Gerber, D. Hall, T. Miyakawa, S. Demars, J.A. Gogos, M. Karayiorgou Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit Proc Natl Acad Sci U S A 100 2003 8993 8998
17. C.R. Gerfen, M. Herkenham, J. Thibault The neostriatal mosaic II Patch- and matrix-directed mesostriatal dopaminergic and nondopaminergic systems. J Neurosci 7 1987 3915 3934
18. M.A. Geyer, K. Krebs-Thomson, D.L. Braff, N.R. Swerdlow Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia a decade in review Psychopharmacology (Berl) 156 2001 117 154
19. T.D. Gould, G. Chen, H.K. Manji In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3 Neuropsychopharmacology 29 2004 32 38
20. F. Hamada, Y. Tomoyasu, Y. Takatsu, M. Nakamura, S. Nagai, A. Suzuki Negative regulation of Wingless signaling by D-axin, a Drosophila homolog of axin Science 283 1999 1739 1742
21. O. Huber, R. Korn, J. McLaughlin, M. Ohsugi, B.G. Herrmann, R. Kemler Nuclear localization of beta-catenin by interaction with transcription factor LEF-1 Mech Dev 59 1996 3 10
22. J. Ichikawa, H.Y. Meltzer Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 1999 90 98
23. S. Ikeda, S. Kishida, H. Yamamoto, H. Murai, S. Koyama, A. Kikuchi Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin EMBO J 17 1998 1371 1384
24. U.G. Kang, M.S. Seo, M.S. Roh, Y. Kim, S.C. Yoon, Y.S. Kim The effects of clozapine on the GSK-3-mediated signaling pathway FEBS Lett 560 2004 115 119
25. S. Kapur, D. Mamo Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1081 1090
26. S. Kapur, G. Remington Dopamine D(2) receptors and their role in atypical antipsychotic action still necessary and may even be sufficient Biol Psychiatry 50 2001 873 883
27. S. Kapur, M.L. Wadenberg, G. Remington Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench Can J Psychiatry 45 2000 241 246
28. S. Kapur, R. Zipursky, C. Jones, G. Remington, S. Houle Relationship between dopamine D(2) occupancy, clinical response, and side effects a double-blind PET study of first-episode schizophrenia Am J Psychiatry 157 2000 514 520
29. T. Katsu, H. Ujike, T. Nakano, Y. Tanaka, A. Nomura, K. Nakata The human frizzled-3 (FZD3) gene on chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility to schizophrenia Neurosci Lett 353 2003 53 56
30. N. Kozlovsky, R.H. Belmaker, G. Agam Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients Am J Psychiatry 157 2000 831 833
31. N. Kozlovsky, R.H. Belmaker, G. Agam Low GSK-3 activity in frontal cortex of schizophrenic patients Schizophr Res 52 2001 101 105
32. N. Kozlovsky, R.H. Belmaker, G. Agam GSK-3 and the neurodevelopmental hypothesis of schizophrenia Eur Neuropsychopharmacol 12 2002 13 25
33. N. Kozlovsky, C. Nadri, R.H. Belmaker, G. Agam Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity Int J Neuropsychopharmacol 6 2003 117 120
34. E.R. Larson, M.A. Ariano D3 and D2 dopamine receptors visualization of cellular expression patterns in motor and limbic structures Synapse 20 1995 325 337
35. M. Lesort, A. Greendorfer, C. Stockmeier, G.V. Johnson, R.S. Jope Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain J Neural Transm 106 1999 1217 1222
36. N. Lijam, R. Paylor, M.P. McDonald, J.N. Crawley, C.X. Deng, K. Herrup Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1 Cell 90 1997 895 905
37. G. Macqueen, T. Young Cognitive effects of atypical antipsychotics focus on bipolar spectrum disorders Bipolar Disord 5 suppl 2 2003 53 61
38. R. McIntyre, M. Katzman The role of atypical antipsychotics in bipolar depression and anxiety disorders Bipolar Disord 5 suppl 2 2003 20 35
39. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 1999 106S 115S
40. J.R. Miller, R.T. Moon Signal transduction through beta-catenin and specification of cell fate during embryogenesis Genes Dev 10 1996 2527 2539
41. C. Nadri, B.K. Lipska, N. Kozlovsky, D.R. Weinberger, R.H. Belmaker, G. Agam Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia Brain Res Dev Brain Res 141 2003 33 37
42. A. Nishi, G.L. Snyder, A.C. Nairn, P. Greengard Role of calcineurin and protein phosphatase-2A in the regulation of DARPP-32 dephosphorylation in neostriatal neurons J Neurochem 72 1999 2015 2021
43. J. Noordermeer, J. Klingensmith, N. Perrimon, R. Nusse dishevelled and armadillo act in the wingless signaling pathway in Drosophila Nature 367 1994 80 83
44. A. Novak, S. Dedhar Signaling through beta-catenin and Lef/Tcf Cell Mol Life Sci 56 1999 523 537
45. W.T. O'Brien, A.D. Harper, F. Jove, J.R. Woodgett, S. Maretto, S. Piccolo Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium J Neurosci 24 2004 6791 6798
46. P. Polakis The adenomatous polyposis coli (APC) tumor suppressor Biochim Biophys Acta 1332 1997 F127 F147
47. E. Richelson Receptor pharmacology of neuroleptics relation to clinical effects J Clin Psychiatry 60 Suppl 10 1999 5 14
48. J. Riese, X. Yu, A. Munnerlyn, S. Eresh, S.C. Hsu, R. Grosschedl LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic Cell 88 1997 777 787
49. G.S. Robertson, H.C. Fibiger Neuroleptics increase c-fos expression in the forebrain contrasting effects of haloperidol and clozapine Neuroscience 46 1992 315 328
50. G.S. Robertson, H. Matsumura, H.C. Fibiger Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity J Pharmacol Exp Ther 271 1994 1058 1066
51. W. Rushlow, C.C. Naus, B.A. Flumerfelt Somatostatin and the patch/matrix compartments of the rat caudate-putamen J Comp Neurol 364 1996 184 190
52. A. Schotte, P.F. Janssen, A.A. Megens, J.E. Leysen Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography Brain Res 631 1993 191 202
53. A. Serretti, D. De Ronchi, C. Lorenzi, D. Berardi New antipsychotics and schizophrenia a review on efficacy and side effects Curr Med Chem 11 2004 343 358
54. V. Sharma Atypical antipsychotics and suicide in mood and anxiety disorders Bipolar Disord 5 Suppl 2 2003 48 52
55. E. Siegfried, T.B. Chou, N. Perrimon wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate Cell 71 1992 1167 1179
56. P. Svenningsson, E.T. Tzavara, R. Carruthers, I. Rachleff, S. Wattler, M. Nehls Diverse psychotomimetics act through a common signaling pathway Science 302 2003 1412 1415
57. F. van Leeuwen, C.H. Samos, R. Nusse Biological activity of soluble wingless protein in cultured Drosophila imaginal disc cells Nature 368 1994 342 344
58. M.L. Wadenberg, S. Kapur, A. Soliman, C. Jones, F. Vaccarino Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats Psychopharmacology (Berl) 150 2000 422 429
59. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641
60. R.S. Williams, L. Cheng, A.W. Mudge, A.J. Harwood A common mechanism of action for three mood-stabilizing drugs Nature 417 2002 292 295
61. L.N. Yatham Acute and maintenance treatment of bipolar mania the role of atypical antipsychotics Bipolar Disord 5 Suppl 2 2003 7 19